+Compare
LIAN
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
159.68M

LIAN Price Prediction, LianBio AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for LIAN with price predictions
08:00 PM EDT Sep 28, 2023

LIAN in -5.62% downward trend, falling for three consecutive days on September 19, 2023

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where LIAN declined for three days, in of 136 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 13, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on LIAN as a result. In of 32 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Aroon Indicator for LIAN entered a downward trend on September 29, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LIAN's RSI Indicator exited the oversold zone, of 14 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for LIAN just turned positive on September 29, 2023. Looking at past instances where LIAN's MACD turned positive, the stock continued to rise in of 16 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LIAN advanced for three days, in of 90 cases, the price rose further within the following month. The odds of a continued upward trend are .

LIAN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.730) is normal, around the industry mean (22.693). P/E Ratio (1.552) is within average values for comparable stocks, (131.605). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.099). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (304.777).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LIAN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I. Advisor
published Earnings

LIAN is expected to report earnings to rise 62.50% to -32 cents per share on December 07

LianBio LIAN Stock Earnings Reports
Q3'23
Est.
$-0.32
Q2'23
Beat
by $0.09
Q1'23
Beat
by $0.07
Q4'22
Beat
by $0.10
Q3'22
Beat
by $0.19
The last earnings report on August 14 showed earnings per share of -20 cents, beating the estimate of -28 cents. With 69.39K shares outstanding, the current market capitalization sits at 159.68M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.19B. The market cap for tickers in the group ranges from 402 to 410.54B. NVO holds the highest valuation in this group at 410.54B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 23%, and the average quarterly price growth was 42%. CRIS experienced the highest price growth at 1,363%, while BCLI experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was 41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
103 Carnegie Center Drive
Phone
+1 609 486-2308
Employees
163
Web
https://www.lianbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRIRX10.970.02
+0.18%
Fidelity Advisor® Real Estate Income I
ADTDX21.43N/A
N/A
Allspring Dynamic Target 2065 Admin
TVOIX31.80-0.07
-0.22%
Touchstone Small Cap Value Institutional
BBLIX12.58-0.04
-0.32%
BBH Select Series - Large Cap
TAIWX9.66-0.04
-0.41%
TIAA-CREF Quant Intl Sm-Cp Eq W

LIAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LIAN has been loosely correlated with FATE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if LIAN jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIAN
1D Price
Change %
LIAN100%
N/A
FATE - LIAN
47%
Loosely correlated
-2.29%
SRNEQ - LIAN
34%
Loosely correlated
-6.19%
AXON - LIAN
34%
Loosely correlated
+1.48%
QNCX - LIAN
32%
Poorly correlated
-4.31%
CERE - LIAN
32%
Poorly correlated
-1.53%
More